Isabel Weigand

1.7k total citations
34 papers, 845 citations indexed

About

Isabel Weigand is a scholar working on Cancer Research, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Isabel Weigand has authored 34 papers receiving a total of 845 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Cancer Research, 25 papers in Surgery and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Isabel Weigand's work include Cancer, Hypoxia, and Metabolism (25 papers), Adrenal and Paraganglionic Tumors (24 papers) and Hormonal Regulation and Hypertension (11 papers). Isabel Weigand is often cited by papers focused on Cancer, Hypoxia, and Metabolism (25 papers), Adrenal and Paraganglionic Tumors (24 papers) and Hormonal Regulation and Hypertension (11 papers). Isabel Weigand collaborates with scholars based in Germany, United Kingdom and Italy. Isabel Weigand's co-authors include Martin Faßnacht, Silviu Sbiera, Matthias Kroiß, Cristina L. Ronchi, Andreas Rosenwald, Timo Deutschbein, Barbara Altieri, Iuliu Sbiera, Bruno Allolio and Davide Calebiro and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Oncogene.

In The Last Decade

Isabel Weigand

32 papers receiving 838 citations

Peers

Isabel Weigand

SURGE

EDM

GENET

Céline Loriot France

Luis Gustavo Perez‐Rivas Germany

Petra Bullova United States

Mélanie Menara France

Zhigang Ji China

Saif S. Al-Sobhi Saudi Arabia

Martine Devillers France

Emma Du United States

Hongchao He China

D. Owensby Australia

Céline Loriot France

Isabel Weigand

485 ×1.0

SURGE

696 ×1.6

351 ×1.0

EDM

424 ×1.8

104 ×0.5

GENET

Citations per year, relative to Isabel Weigand Isabel Weigand (= 1×) peers Céline Loriot

Countries citing papers authored by Isabel Weigand

Since Specialization

Citations

This map shows the geographic impact of Isabel Weigand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Weigand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Weigand more than expected).

Fields of papers citing papers by Isabel Weigand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Weigand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Weigand. The network helps show where Isabel Weigand may publish in the future.

Co-authorship network of co-authors of Isabel Weigand

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Weigand. A scholar is included among the top collaborators of Isabel Weigand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Weigand. Isabel Weigand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maier, Tanja, Stefan Kircher, M. Schauer, et al.. (2025). Wnt/β-catenin pathway activation is associated with glucocorticoid secretion in adrenocortical carcinoma, but not directly with immune cell infiltration. Frontiers in Endocrinology. 16. 1502117–1502117.

Ruggiero, Carmen, Elisa Rossini, Giulia Cantini, et al.. (2023). FSCN1 as a new druggable target in adrenocortical carcinoma. International Journal of Cancer. 153(1). 210–223. 11 indexed citations

Corradini, Stefanie, Max Seidensticker, Petra Zimmermann, et al.. (2023). High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series. Hormone and Metabolic Research. 56(1). 30–37. 4 indexed citations

Wang, Qian, Na Sun, Ronan Le Gleut, et al.. (2023). Metabolic heterogeneity in adrenocortical carcinoma impacts patient outcomes. JCI Insight. 8(16). 5 indexed citations

Mueller, Jonathan Wolf, et al.. (2021). Steroid Sulfation in Adrenal Tumors. The Journal of Clinical Endocrinology & Metabolism. 106(12). 3385–3397. 10 indexed citations

Sbiera, Iuliu, Markus Krebs, Silviu Sbiera, et al.. (2021). High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. Prostate Cancer and Prostatic Diseases. 25(3). 484–490. 20 indexed citations

Weigand, Isabel, Barbara Altieri, Vittoria Basile, et al.. (2020). Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. The Journal of Clinical Endocrinology & Metabolism. 105(8). 2642–2653. 21 indexed citations

Weigand, Isabel, Stefan Kircher, Barbara Altieri, et al.. (2020). Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology. 11. 219–219. 27 indexed citations

Weigand, Isabel, Jochen Schreiner, Florian Röhrig, et al.. (2020). Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death and Disease. 11(3). 192–192. 47 indexed citations

10.

Bathon, Kerstin, Isabel Weigand, Jens T. Vanselow, et al.. (2019). Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. Endocrinology. 160(2). 447–459. 35 indexed citations

11.

Weigand, Isabel. (2018). Pathogenesis of benign unilateral adrenocortical tumors: focus on cAMP/PKA pathway. PubMed. 44(1). 25–32. 1 indexed citations

12.

Sbiera, Silviu, Sabine Kendl, Isabel Weigand, et al.. (2018). Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. Molecular and Cellular Endocrinology. 480. 36–41. 5 indexed citations

13.

Weigand, Isabel, Barbara Altieri, Stefan Kircher, et al.. (2018). New cancer drug targets identified in adrenocortical carcinoma through gene expression profiling. Endocrine Abstracts. 1 indexed citations

14.

Appenzeller, Silke, Silviu Sbiera, Stefan Kircher, et al.. (2018). Targeted molecular analysis in adrenocortical carcinomas: a way towards improved personalized prognostication. Endocrine Abstracts. 1 indexed citations

15.

Weigand, Isabel, Cristina L. Ronchi, Marthe Rizk‐Rabin, et al.. (2017). Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. Scientific Reports. 7(1). 49–49. 17 indexed citations

16.

Ronchi, Cristina L., Erika Peverelli, Sabine Herterich, et al.. (2016). Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. European Journal of Endocrinology. 174(3). 363–372. 82 indexed citations

17.

Sbiera, Silviu, Marianna A. Tryfonidou, Isabel Weigand, et al.. (2016). Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. PLoS ONE. 11(12). e0169009–e0169009. 6 indexed citations

18.

Altieri, Barbara, Silviu Sbiera, Silvia Della Casa, et al.. (2016). Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget. 8(6). 9323–9338. 28 indexed citations

19.

Röhrig, Florian, Sandra Vorlová, Martin Wartenberg, et al.. (2016). VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. 36(1). 1–12. 43 indexed citations

20.

Sbiera, Silviu, Timo Deutschbein, Isabel Weigand, et al.. (2015). The New Molecular Landscape of Cushing's Disease. Trends in Endocrinology and Metabolism. 26(10). 573–583. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact